Cipla has achieved a significant regulatory milestone with the U.S. FDA approval for its first AB-rated generic version of Ventolin HFA. The company announced this development through a regulatory filing under Regulation 30 of SEBI listing requirements, marking a major advancement in its respiratory portfolio and strategic positioning in the lucrative U.S. pharmaceutical market.

Regulatory Approval and Product Details

Cipla USA Inc., the wholly owned subsidiary of Cipla Limited, received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application (ANDA) for Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation. This represents the first AB-rated generic therapeutic equivalent of Ventolin HFA, originally marketed by GlaxoSmithKline.

The medication is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged four years and older with reversible obstructive airway disease, as well as for the prevention of exercise-induced bronchospasm in patients aged four years and older.

Launch Timeline and Manufacturing Strategy

The company expects to launch this generic product during H1 of FY 2026-27, allowing sufficient time for manufacturing scale-up and market preparation. The product will be manufactured at Cipla's newly constructed, dedicated inhalation facility in Fall River, Massachusetts, reinforcing both supply resilience and domestic manufacturing footprint.

Executive Commentary and Strategic Impact

Commenting on the approval, Achin Gupta, Managing Director & Global CEO of Cipla Limited, stated: "This marks an important milestone for Cipla and reflects our strong scientific and regulatory capabilities in complex inhalation products. Lung health remains at the heart of all our offerings and follows a singular, distilled objective, to build a sustainable and differentiated portfolio for patients globally."

Marc Falkin, Chief Executive Officer of Cipla North America, added: "Strengthening our U.S. respiratory franchise, the product will be manufactured at our newly constructed, dedicated inhalation facility in Fall River, Massachusetts, reinforcing both supply resilience and our domestic manufacturing footprint. With planned volume ramp-up, we expect to drive meaningful difference in the lives of patients."

Market Position and Portfolio Enhancement

This FDA approval significantly enhances Cipla's U.S. respiratory portfolio, providing access to the total U.S. albuterol market valued at approximately USD 1.50 billion according to IQVIA. The approval reinforces Cipla's leadership in the albuterol inhalation category, with approved generics for both Ventolin HFA and Proventil HFA.

The product is backed by Cipla's vertically integrated inhalation platform, reflecting the company's continued investment in U.S.-based manufacturing for complex respiratory therapies. This strategic positioning allows Cipla to leverage its established distribution networks and regulatory expertise to maximize market penetration in the substantial U.S. respiratory therapeutics segment.

Cipla has received two Form 483 observations following a U.S. Food and Drug Administration inspection of its manufacturing facility in Verna, Goa. The pharmaceutical company disclosed this development through an official notification to stock exchanges under Regulation 30 of SEBI listing requirements.

FDA Inspection Details

The U.S. FDA conducted a comprehensive inspection of Cipla's Goa manufacturing facility from April 6-17, 2026. The inspection served a dual purpose as both a routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI).

Form 483 Observations and Company Response

Upon conclusion of the inspection, Cipla received two inspectional observations in Form 483. Form 483 is an official FDA document that lists observations made during inspections of pharmaceutical facilities, typically highlighting areas where current good manufacturing practices may need improvement.

Cipla has committed to working closely with the USFDA to address these observations comprehensively within the stipulated timeframe. The company's proactive approach demonstrates its commitment to maintaining regulatory compliance and quality standards.

Regulatory Compliance Framework

The inspection represents part of the FDA's ongoing oversight of pharmaceutical manufacturing operations. Such inspections are routine regulatory activities designed to ensure pharmaceutical manufacturers maintain compliance with established quality and safety standards. The company has formally notified major stock exchanges including BSE, NSE, and Societe de la Bourse de Luxembourg about this development.

Market Impact and Outlook

Cipla's transparent disclosure of the FDA inspection results reflects the company's commitment to regulatory compliance and stakeholder communication. The pharmaceutical company's willingness to address the observations within stipulated timelines indicates a structured approach to maintaining international quality standards for its manufacturing operations.